Research Comparison
GLP-3 (Reta) vs GLP-2 (Tirz)
GLP-3 (Reta) and GLP-2 (Tirz) are often compared because both sit in metabolic research. GLP-3 (Reta) acts on GLP-1 + GIP + glucagon (triple agonist) and is studied for metabolic & body-weight research, while GLP-2 (Tirz) acts on GLP-1 + GIP (dual agonist) and is studied for metabolic & body-weight research. Both are supplied as lyophilized powder for in-vitro laboratory research only — this page compares mechanism and research status, not dosing or human use.
GLP-3 (Reta)
Metabolic
GLP-2 (Tirz)
Metabolic
Frequently asked
- What is the difference between GLP-3 (Reta) and GLP-2 (Tirz)?
- The main difference is mechanism and research stage. GLP-3 (Reta) targets GLP-1 + GIP + glucagon (triple agonist) (phase 3 (investigational)) and is studied for metabolic & body-weight research; GLP-2 (Tirz) targets GLP-1 + GIP (dual agonist) (approved formulations exist) and is studied for metabolic & body-weight research. Both are research-use-only compounds, not for human or animal use.
- Are GLP-3 (Reta) and GLP-2 (Tirz) approved for human use?
- No. Renova Wellness supplies both strictly for in-vitro laboratory and scientific research use only. Research status differs — GLP-3 (Reta): phase 3 (investigational); GLP-2 (Tirz): approved formulations exist — but neither is sold for human or animal consumption, and no medical, therapeutic, or dosing claims are made.
- How is purity verified for GLP-3 (Reta) and GLP-2 (Tirz)?
- Every lot of both compounds ships with its own per-batch Certificate of Analysis — identity by mass spectrometry, ≥98% purity by HPLC, and a unique lot number you can verify against the vial in your hand.
Key research terms
Related comparisons
Build a multi-compound set in the Stack Builder or run the reconstitution calculator.
Research references
Primary literature for GLP-3 (Reta) and GLP-2 (Tirz). Provided for scientific context only — not medical or dosing guidance.
- Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. PMID 37366315 →
- Rosenstock J, et al. Retatrutide for people with type 2 diabetes: a randomised phase 2 trial. Lancet. 2023. PMID 37385280 →
- Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Ther. 2021. PMID 33325008 →
- Karagiannis T, et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022. PMID 35579691 →
Research use only. This comparison covers mechanism, target, and research status. It is not medical, therapeutic, or dosing advice. Compounds sold by Renova Wellness™ are for in-vitro laboratory research and are not for human or animal consumption.